To design a novel system of scoring prune belly syndrome (PBS) phenotypic severity at any presenting age and apply it to a large pilot cohort.
Introduction
Prune belly syndrome (PBS), also known as Eagle-Barrett syndrome, is a phenotypically variable congenital multisystem myopathy of mild to lethal severity affecting 3.8/100 000 live male births [1] . Despite advances in medical and surgical management, newborn mortality remains high at 23-29%, unimproved from mortality rates reported in earlier cohorts [1] [2] [3] . And although rare, PBS contributes disproportionately to healthcare costs, as many patients with PBS require renal replacement therapy in early childhood: 2.5% of North American paediatric renal transplants and 4.2% of European paediatric renal replacements are for a diagnosis of PBS [4, 5] . Managing patients with PBS who survive the neonatal period is a formidable challenge for paediatric and adult specialists, as no consensus on treatment strategies exists. Individual practitioners may encounter only a few affected patients in the course of a career, and evidence-based guidance has been limited by small sample sizes and retrospective approach. The need for collaborative, prospective randomised studies assessing specific treatment outcomes is broadly recognised [6] .
Current study designs are hindered by the wide heterogeneity of the PBS phenotype and the absence of any unified method to classify phenotypic severity [7] , making it difficult to compare patients and their outcomes [8] . This also limits investigators' ability to identify phenotypically distinct patients with PBS whose unique features may represent a specific genetic aetiology. The only existing phenotypic categorisation of PBS severity, cogently devised by Woodard [9] in 1985, divides newborns into three groups based on clinical parameters and immediacy of life-supporting surgical management required by the child. While Woodard's classification is useful in broadly prioritising the patient's care and management, it is limited by the lack of phenotypic granularity.
Recognising these barriers to improved PBS research and treatment, we hypothesise that a more expansive, two-fold classification system will better describe the phenotypic diversity of patients with PBS. First, to facilitate PBS phenotyping, we created a novel, pragmatic, numerically continuous scoring system called 'RUBACE' (R: renal, U: ureter, B: bladder/outlet, A: abdominal wall, C: cryptorchidism, E: extra-genitourinary [GU] ), designed to quantitatively grade the phenotypic severity of a patient with PBS. Second, we borrowed from the genetics literature a methodology wherein patients with a complex trait are partitioned into phenotypic subcategories. The classic prune triad (deficient midline abdominal musculature, urinary tract distension, and cryptorchidism) typically occurs in isolation, and we define this group as 'isolated PBS' (Fig. 1 ) [10] [11] [12] [13] [14] [15] [16] .
However, many patients with PBS have extra-GU malformations outside the typical PBS phenotype, which we have sub-classified into two categories: 'syndromic PBS' and 'PBS-plus'. In syndromic PBS, the extra-GU features meet criteria for a known genetically defined syndrome, association or condition. In PBS-plus, there are extra-GU malformations outside the isolated PBS phenotype that falls short of a distinct genetically defined disease/syndrome/association. We applied the RUBACE and Woodard scoring systems and these PBS subcategories to a large pilot cohort of patients with PBS for individualised phenotyping.
Patients and Methods
From 2000 to 2017, living patients diagnosed with PBS were recruited to our institution's prospective clinical and genetic study (National Institute of Health [NIH] grant R01 DK105068, Principal Investigator: L. Baker). To facilitate to this investigation, we designed a pragmatic, numerical PBSseverity scoring system to grade patients of any age based on six sub-scores (R: renal, U: ureter, B: bladder/outlet, A: abdominal wall, C: cryptorchidism, and E: extra-GU [RUBACE]), yielding a potential summed score of 0-31 (Table 1) . Medical records for patients were reviewed for Prune Belly Syndrome Isolated PBS 'Plus' or Syndromic
PBS-Plus Syndromic
Affected individual has classic triad of lax abdominal musculature, distended urinary tract, and bilateral cryptorchidism (males). This includes patients with sequelae of the classic triad such as pulmonary hypoplasia, weak cough, constipation, or scoliosis (n = 39)*
In addition to the classic triad, the affected individual has additional malformations (usually extra-genitourinary) unexplained by the triad's sequelae.
The additional malformations do not occur in a pattern recognized as a known syndrome or a genetic condition.
The additional malformations meet criteria for a known syndrome or genetic condition.
• Hepatoblastoma(n = 5) *,a,b • Hearing loss (n = 2) * • Infantile stroke + optic nerve atrophy (n = 1) *,a,b • Early gout + T2DM + pancreatic atrophy (n = 1) c • Pupils nonreactive to light (mydriasis) (n = 2) d,e
• Duchenne Muscular Dystrophy (n = 1)* • Pierre Robin Sequence (n = 2)* • VACTERL (n = 13) *,f • MMIHS (n = 1) g Fig. 1 Overview: the PBS phenotype may be categorised into isolated, PBS-plus, and syndromic PBS based on the presence of additional malformations cross-sectional application of RUBACE. Patients were scored by two providers (N.M.P and M.K.A). Any discrepancy in scoring was resolved by joint re-examination of the patient record and consensus.
Data Sources and Selection of the Score Date
With Institutional Review Board approval, complete medical records were solicited from recruited patients on a voluntary basis. Electronic medical records were also reviewed for recruited patients treated at our tertiary children's hospital. Because these complex children often receive care at multiple facilities with redundancy of evaluation, patients were scored at a single point in time using an individually assigned score date. This score date was selected based on the most recent inpatient encounter, wherein there was sufficient imaging, laboratory, and physical examinations and/or operative notes to establish the patient's severity in each of the six RUBACE subcategories. Patients with records insufficient for scoring were excluded.
RUBACE Subcategory Grading and Severity Scoring
The rubric-guiding PBS RUBACE scoring is seen in Table 1 . In each applicable subcategory, patients with normal anatomy without pathology should receive zero points.
RUBACE renal (R) scoring (maximum: 6 points) corresponds to the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) GFR severity categories (reported in mL/min/ 1.73 m 2 ). KDIGO GFR categories G1-2, G3a-b, G4 and kidney failure (GFR <15 mL/min/1.73 m 2 ) receive RUBACE R scoring of 1, 2, 3, and 4, respectively [17] . GFR should be calculated per KDIGO-referenced creatinine-based or cystatin C-based equations for children or adults, as appropriate. Additional RUBACE R points are awarded for very young age (<2 years, 2 points) and pre-adolescent age (<13 years, 1 point) based on the rational that renal stress is greater during major growth periods.
For the ureter (U) sub-score (maximum: 3 points), initial and interval assessment of VUR should be per AUA guidelines [18] . 'High'-grade VUR corresponds to an International Reflux Grading Scale of III-V. Whilst the 'gold standard' for VUR assessment is voiding cystourethrography and/or videourodynamics, ultrasonographic findings may be used in proxy. Other imaging studies that measure ureter girth are also acceptable measures of severity, as distal ureteric diameter has been shown to predict breakthrough febrile UTIs and VUR outcomes [19, 20] . Current ureterostomy or nephrostomy for ureteric obstruction should be scored 3 points; however, ureters status after correction (e.g., ureteroureterostomy, reimplant) merits only 2 points.
For bladder/outlet severity (B, maximum: 3 points), 'urotherapy' is per ICS definitions of treatment models for bowel and bladder dysfunction [21] . Patients given pharmacological therapy to aid voiding and patients given antibiotic prophylaxis against UTI are awarded 2 points. Surgical diversion such as vesicostomy merits 3 points; however, other surgical procedures, such as augmentation or reduction cystoplasty, should not receive 3 points. A child who underwent surgical diversion at an early age but currently voids per urethra should not receive 3 points.
Judgement of abdominal (A) wall laxity severity (maximum: 2 points) has not been standardised, and thus, we propose our subjective categorisation unless an imaging modality has shown clear absence of ventral abdominal wall musculature (2 points). Subjectively, the mild abdominal phenotype has a protuberant, lax, mildly contractile belly with minimal to no wall thinning or wrinkles (1 point, Fig. 2A ). In contrast, the severe, classic prune belly appearance (2 points, Fig. 2B ) is a strikingly thin, floppy, non-contractile abdominal wall with lateral sagging, protrusion of the abdominal organs, and moderate to severe skin wrinkling. Eventration in the left or right upper quadrant may be significant. Bowel loops and peristalsis are often visible beneath the skin. Children being scored status post-abdominoplasty are awarded 2 points unless they are able to perform a sit-up unassisted, which receives 1 point.
Definitions and categories of cryptorchidism (C, maximum: 2 points) are per previously established guidelines [22] . Bilateral, impalpable testes should be scored 2 points. Patients found to have inguinoscrotal or unilaterally undescended testes should be scored 1 point. Surgical history of orchidopexy for bilateral intra-abdominal testes (e.g., FowlerStephens) may be used in proxy to score older patients who have surgically descended testes. Males with normally descended testes should not be awarded any points in this category. XX female patients are awarded 1 point to permit application of RUBACE to female PBS candidates.
The five extra-GU (E) sub-scores (neurological, cardiac, gastrointestinal [GI], musculoskeletal, and respiratory) are generated based on the decades of literature reporting cases of PBS with extra-GU disease, as well as the authors' experience managing a sizable patient cohort [1, 7, 8] . The E sub-score is the most variable (maximum: 15 points). It is acknowledged that subtler symptoms (e.g., constipation, asthma, and scoliosis) may not reveal themselves until later childhood, resulting in a score of zero in many patients, particularly newborns. Infant patients should be scored as completely as possible based on their standard-of-care evaluations, and their score and categorisation may be readjusted as they age. 
Phenotypic Categorisation of PBS: Isolated PBS, Syndromic PBS, and PBS-plus
Patients were assigned to one of three categories (isolated PBS, syndromic PBS, or PBS-plus) based on the following criteria. Scores of 0-2 in any E subcategory and a score of 0-3 in the respiratory category were consistent with the typical PBS phenotype (isolated PBS). A score of 3 points in either the neurological, cardiac, GI, or musculoskeletal E categories indicated syndromic PBS or PBS-plus.
Comparison to Woodard Categorisation
Using the same medical records, patients were assigned Woodard categories based on his original description of the PBS spectrum [9] . The mean RUBACE scores for each Woodard category were compared with one-way ANOVA. All statistical analyses were performed with GraphPad Prism (GraphPad Software, La Jolla, CA, USA).
Results
Of 138 patients with PBS recruited to our study, medical records were acquired for 54 patients: 30 patients with local electronic medical records and 24 with external hospital records from 19 cities, including two international patients. Four patients were excluded due to incomplete records. In all, 50 patients (48 male, two female) with a diagnosis of PBS were scored at a median (interquartile range [IQR]) age of 6.0 (1.1-11.8) years. In all, 18 patients were aged <2 years at scoring, and four were scored during the first month of life. Patient cohort characteristics and demographics are described in Table 2 .
The histogram of RUBACE scores, as well as distributions of RUBACE scores, is seen in Fig. 3 . The distribution by individual sub-scores is shown in Fig. S1 . When stratified by Woodard category, the mean RUBACE scores were 20.5 (eight patients), 13.8 ( 25) , and 10.6 (17), for categories 1, 2 and 3, respectively (P < 0.001, Fig. 4 ) [17] . Segregated by phenotypic categories, 39 patients were isolated PBS (78%), six were syndromic PBS (12%), and five were PBS-plus (10%). The syndromic PBS included three patients with VACTERL association (Vertebral defects, Anal atresia, Cardiac defects, Tracheo-Esophageal fistula, Renal anomalies, and Limb abnormalities), two with familial Pierre Robin Sequence (PRS), and one with Duchenne muscular dystrophy (DMD).
The two lowest RUBACE scoring patients had unconvincing phenotype for full classic PBS triad (Fig. 3B) : one noncryptorchid male with posterior urethral valves whose kidney and ureteric function normalised after cystoscopic valve ablation, and one female with complex large chromosomal 
Discussion
During our NIH-funded genetics investigation on PBS, we realised improved phenotyping would be required to advance research and treatment for these diverse, medically and surgically complex patients. Thus, we developed the first detailed histogram to illustrate PBS severity in a population, stratifying the severity of the classic Eagle-Barrett 'triad' (RUBAC), as well as the severity of extra-GU features (E). Combined, these two numbers yield the patient's RUBACE score. In its simplest application, this graphic (Fig. 3 pathognomonic for PBS. However, we would encourage our stricter diagnostic criteria, as BOO from other aetiologies (posterior urethral valves, cloaca, etc.) may be part of or mimic the classic PBS phenotype. A future direction of the present study will be to validate the RUBACE scoring system against unaffected children and children with PBS mimickers in order to establish diagnostic thresholds.
The overlying goal of RUBACE was to transform PBS care, as suboptimal clinical management of this chronic disease contributes to major healthcare burdens, such as dialysis or transplant. We thus desired to add functional breadth to the classic Woodard spectrum without violating his original principles. In this, we were successful: as expected, higher RUBACE scores significantly and inversely correlated with Woodard category (Fig. 4) . Woodard 1 patients had distinguishably higher RUBACE scores than Woodard 2 patients due to characteristic of renal or respiratory failure. In contrast, overlap was seen in the RUBACE ranges of the Woodard 2 and 3 patients. To illustrate: of the four patients that scored a RUBACE of 13, two were Woodard 2, with impaired renal function, prominent VUR, and either vesicostomy or appendicovesicostomy (APV), and two were Woodard 3, with much better urological function but also possessing skeletal and GI features. Whilst the overall RUBACE scores of all were equal, comparison of these patients side by side via the granular, separate, system-based RUBACE score yields a detailed phenotypic picture of each child, much of which is lost in the Woodard classification. The Woodard 2 and 3 categories are primarily segregated by progressive loss vs maintenance of renal function. By incorporating the KDIGO classification, renal function is clearly quantified. Thus, RUBACE was not designed to copy the Woodard classification but instead to spread out and grade the phenotypic spectrum that these patients exhibit. Spreading out the PBS phenotypic spectrum will be extremely useful, as PBS cohorts could be case matched based either on summative RUBACE or on individual sub-scores to target specific treatment outcomes in multicentre prospective or case-controlled studies.
While it is a great challenge to improve clinical care, outcomes and research in a rare disease such as PBS, the concept is not unproven. Cystic fibrosis (CF) is another heterogeneous disease conferring great medical socioeconomic burden, particularly in patients progressing to respiratory failure and lung transplant [23] . Outcomes for patients with CF have improved dramatically in recent years, with a 17% reduction in mortality from 2000 to 2010 [24] . Although partially owed to new technology and medications, improvements stem from enhancements in the delivery of care. The lynchpin of this enhancement was the creation of a sophisticated patient clinical research registry that unified centre processes and outcomes, facilitating higher level evidence, which eventually produced treatment guidelines and proven standards of care [25] . While it may take more years to achieve enhanced healthcare for PBS, RUBACE offers a common language to providers worldwide and provides the framework for a sophisticated PBS patient registry to design long-awaited prospective studies.
A second framework we hope to provide with RUBACE is the ability to bridge phenotype to genotype. RUBACE is not the first proposed bridge to genotype in rare disease: integrating detailed standardised phenotypic severity scores with genotype has been previously demonstrated for conditions such as X-linked myotubular myopathy and facioscapulohumeral muscular dystrophy [26, 27] . The use of detailed phenotyping to identify phenotypically unique subgroups has been highly successful at identifying causal DNA variants. Urologists have encountered this concept previously in the case of Wilms' tumour, a genetically heterogeneous disease that occurs both in isolation and also as part of more complex syndromes, such as WAGR (Wilms' tumour, Aniridia, Genitourinary abnormalities/gonadoblastoma, and mental Retardation) syndrome, Beckwith-Weidermann syndrome (BWS), and Denys-Drash syndrome (DDS) [28] . In the case of WAGR syndrome, a contiguous gene syndrome, the constellation of multisystem anomalies was found to occur in individuals with deletions in 11p13 [29] . Years of focused study using these syndromic patients was integral to discovery and mapping of the Wilms tumour 1 [30, 31] . Concomitantly, this mapping yielded the causal mutation for BWS in 11p15.5 [32, 33] . In a similar fashion, investigation of six patients possessing both tuberous sclerosis (TSC) and severe infantile polycystic disease led to greater understanding of the role polycystic kidney disease 1 (PKD1) deletions play in patients with TSC with profound phenotypic severity [34] .
Targeting children with PRS-plus, namely those with extraskeletal anomalies, similarly supported the theory that dysregulation of Sex-Determining Region Y-Box 9 (SOX9) is responsible for PRS's pathogenesis [35] . Although genetic understanding of PBS is still in its early stages, stratifying patients for targeted candidate gene investigation is an important collaborative effort for this rare disease, and a current aim of our NIH study.
We found that 12% of our present cohort had syndromic PBS: three had VACTERL association, two half-brothers had PRS, and one patient had DMD (Fig. 1) . Five patients met criteria for PBS-plus: one child with PBS-plus hepatoblastoma and autism; one with PBS-plus seizures, infantile stroke, and optic nerve atrophy; two with PBS-plus hearing loss; and finally the one female patient we suspect is not PBS. With respect to syndromic, there have been prior cases of VACTERL reported in association with PBS, although the cause behind this is still undetermined [10, 36] . Additionally, a prior case series reported four patients with PBS-plus hepatoblastoma [11] . However, whilst the genetic and molecular bases of DMD are well established (OMIM#310200, Xp21.2-21.1) and causal genes for PRS have been recently described [35] , neither DMD nor PRS have yet been shown to have association with PBS. With continued application, RUBACE may uncover additional syndromes not previously reflected in the literature, giving new leads into the aetiology of this complex disorder.
There were several controversial points to be addressed in designing RUBACE. One controversy was the decision to include and score female patients. There is a case to be made for female patients not meeting the diagnostic criteria for PBS, as they cannot be cryptorchid. This, in conjunction with the evidence of X-linked recessive inheritance in several multiplex families [37] has led some to suspect that females cannot have true PBS. However, we believe it is important to continue studying female prunes and female pseudo-prunes for several reasons. First, the literature describes several cases of female patients with PBS; due to their rarity, these descriptions have been very phenotypically detailed, including the variant Mullerian anatomy and also extra-GU features, such as malformations suggestive of VACTERL [38] [39] [40] [41] . These extra-GU features (particularly those that appear syndromic) provide salient targets for genetic investigation, even for pseudo-prunes, as they may represent a milder expression of causal mutations vs other syndromes with overlapping pathogenesis. Furthermore, DNA variations in four autosomal genes [cholinergic receptor muscarinic 3 (CHRM3); hepatocyte nuclear factor 1b (HNF1b); actin, a 2 , smooth muscle, aorta (ACTA2); and actin, c 2 , smooth muscle, enteric (ACTG2)] have been associated with five sporadic PBS cases [12, 37, 42] and one PBS multiplex consanguineous kindred [13] . DNA variants in these autosomal genes would manifest theoretically in females at near equal frequency as in males. Including females also allows us to test RUBACE as a diagnostic tool: validation against known non-PBS female uropathies could yield firm score thresholds, which would be of great value to the urologist presented with the rare female patient.
An additional controversial point was how to create scoring applicable to newborns, young children before surgery, and those of any age after surgeries. By testing the severity score on this broad age range at a single point in time, it improved the rubric by challenging us to consider all contingencies and surgical states. However, some of our assigned scores can be debated. For example, we scored ureteric reconstruction a U-score of 2 points (U2) on the assumption that the surgery improved the previous ureteric pathology. In contrast, we scored ureterostomy (U3) on the belief that this indicated severe ureteric disease with a 'yet to be decided' long-term outcome.
Similarly, a B2 score for a child on urethral clean intermittent catheterisation (CIC) could be considered to be equally pathological as CIC via APV (which we scored B3). However, we feel these are different, as urethral CIC may be only needed temporarily until the child ages and becomes cooperative for urotherapy such as double/triple timed voiding. In our eyes, the creation of an APV indicates that the incomplete bladder emptying is felt to be a fixed problem warranting a permanent surgical solution. Concerning preemptive vesicostomy (which we scored B3), it typically indicates a severely affected PBS bladder and outlet; however, this could be debated as the long-term outcome is also yet to be decided. It is likely that patients with PBS will need to be re-scored intermittently. Should RUBACE be universally adopted to score PBS newborns, scoring for various segments of care can be created and the proxies we have created could be eliminated. Thus, RUBACE could be used longitudinally to evaluate treatment outcomes.
The RUBACE system has several limitations. While every attempt was made to incorporate professional/expert guidelines into the scoring, components of RUBACE are supported by expert opinion. For example, the least defined subcategory is the abdomen, with highly subjective scoring criteria and undeniable impact upon several of the extra-GU scores. More qualitative and quantitative functional measures need to be developed for the abdominal phenotype, as the diminished muscular function of the PBS ventral abdominal wall plays key roles in respiratory, musculoskeletal, GI, and urinary tract health. Additionally, RUBACE was designed to be a pragmatic score, derivable from the medical record of any patient with PBS receiving the standard of care. While some of the RUBACE sub-group scores could have been defined using more quantitative studies that are occasionally used and needed in the clinical care of patients with PBS (e.g., urodynamics or pulmonary function tests), these were not incorporated into the scoring system due to limited global availability. As our present study was a cross-sectional study, we did not try to show that RUBACE correlates with outcomes. We hope that longitudinal studies of PBS cohorts employing this scoring system or future revisions of it can define whether RUBACE correlates with outcomes. Finally, as we only scored living patients, RUBACE may not be generalisable to patients with PBS who died in utero or in the perinatal period.
Conclusion
The RUBACE score is a practical phenotyping tool that grades individual patient severity at the organ/system level, illustrates the full distribution of PBS severity within a cohort, aids phenotypic categorisation into isolated PBS, syndromic PBS, and PBS-plus groups, and lays the groundwork on which genotype-phenotype correlations and standardised, quality studies assessing medical and surgical treatment outcomes may be built.
